Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Wong MK. et al, (2025), J Clin Oncol

Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England

Buckell J. et al, (2025), British Journal of Cancer

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

Milotay G. et al, (2025), Nature Medicine

Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.

Dummer R. et al, (2025), Clin Cancer Res

Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity.

Go S. et al, (2024), Elife, 13

Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity

Go S. et al, (2024), eLife, 13

Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.

Jackson A. et al, (2024), Lancet Oncol, 25, 1476 - 1486

Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy

Milotay G. et al, (2024)

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.

Weber JS. et al, (2024), J Clin Oncol

A retrospective analysis of the validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries

Jackson A. et al, (2024), The Lancet Oncology

Immune Microenvironment Modulation following Neo-adjuvant Therapy for Oesophageal Adenocarcinoma: A Translational Analysis of the DEBIOC Clinical Trial

Scanlon E. et al, (2024), ESMO Open

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.

Hamid O. et al, (2024), J Clin Oncol

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

Luke JJ. et al, (2024), J Immunother Cancer, 12

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.

Elez E. et al, (2024), BMC Cancer, 24

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Watson RA. et al, (2024), Journal for immunotherapy of cancer, 12

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.

Larkin J. et al, (2024), Cell Rep Med, 5

Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity

Go S. et al, (2023)

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.

Carroll TM. et al, (2023), Cancer Cell, 41, 1222 - 1241.e7

Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.

Nicholson BD. et al, (2023), Lancet Oncol

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.

Hamid O. et al, (2023), J Immunother Cancer, 11

1
2
3
4
5
6
7
...
»